The paradox of arsenic: Molecular mechanisms of cell transformation and chemotherapeutic effects

Critical Reviews in Oncology/Hematology

Volumn 42, Issue 1, 2002, Pages 5-24

  Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Activator protein 1; Apoptosis; Cancer; JB6 epidermal cells; Mitogen activated protein kinase; Nuclear factor kappa B; Tumor

Indexed keywords

ARSENIC; ARSENIC ACID; CACODYLIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHANEARSONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; TUMOR PROMOTER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL TRANSFORMATION; DNA BINDING; DNA DAMAGE; DNA SYNTHESIS; HUMAN; MOUSE; NONHUMAN; OXIDATIVE STRESS; RAT; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR PROMOTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENIC; ARSENICALS; CELL TRANSFORMATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 0036118599     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00215-3     Document Type: Review

References (195)

1. Arsenic: health effects, mechanisms of actions, and research issues
2. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors
3. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms?
4. Predisposing factors in occupational lung cancer: inorganic minerals and chromium
5. Risk of internal cancers from arsenic in drinking water
6. Arsenic in drinking water and bladder cancer
7. Confounding variables in the environmental toxicology of arsenic
8. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species
9. 3) in the treatment of acute promyelocytic leukemia
10. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia
11. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
12. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
13. Retinoids in chemoprevention and differentiation therapy
14. Recent advances in the treatment of acute leukemia: 1999
15. Biology and treatment of acute progranulocytic leukemia
16. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy
17. Successful treatment of all-trans retinoic acid resistant and chemotherapy naive acute promyelocytic patients with arsenic trioxide-two case reports
18. Arsenicals in hematologic cancers
19. Current issues in the management of acute promyelocytic leukemia
20. The enigma of arsenic carcinogenesis: role of metabolism
21. Is the human carcinogen arsenic carcinogenic to laboratory animals?
22. In vitro tissue specificity for arsine and arsenite toxicity in the rat
23. Requirement of Erk, but not JNK, for arsenite-induced cell transformation
24. Effects of arsenic on blast transformation and DNA synthesis of human blood lymphocytes
25. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression
26. Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure
27. Effects of dietary dimethylarsinic acid on the urine and urothelium of rats
28. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats
29. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity
30. Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue
31. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic
32. Enzymatic reduction of arsenic compounds in mammalian systems: reduction of arsenate to arsenite by human liver arsenate reductase
33. DMPS-arsenic challenge test. II. Modulation of arsenic species, including monomethylarsonous acid (MMA(III)), excreted in human urine
34. Folic acid protects SWV/Fnn embryo fibroblasts against arsenic toxicity
35. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes
36. Arsenic species that cause release of iron from ferritin and generation of activated oxygen
37. Arsenic methylation capacity and skin cancer
38. The role of orally administered dimethylarsinic acid, a main metabolite of inorganic arsenics, in the promotion and progression of UVB-induced skin tumorigenesis in hairless mice
39. 72-kDa stress protein (hsp72) induced by administration of dimethylarsinic acid to mice accumulates in alveolar flat cells of lung, a target organ for arsenic carcinogenesis
40. Promotion of skin carcinogenesis by dimethylarsinic acid in keratin (K6)/ODC transgenic mice
41. Metals and disorders of cell accumulation: modulation of apoptosis and cell proliferation
42. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation
43. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase
44. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices
45. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation
46. Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation
47. No point mutation of Ha-ras or p53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants
48. Responses of preneoplastic epidermal cells to tumor promoters and growth factors: use of promoter-resistant variants for mechanism studies
49. Tumour promoter induces anchorage independence irreversibly
50. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF
51. The stress-activated protein kinase subfamily of c-Jun kinases
52. MAPKs: new JNK expands the group
53. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation
54. Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
55. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK
56. Apoptosis induction by arsenic: mechanisms of actions and possible clinical applications for treating therapy-resistant cancers
57. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway
58. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite
59. Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase
60. Different mechanisms of c-Jun NH2-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors
61. Signal transduction pathways regulated by arsenate and arsenite
62. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors
63. Arsenic induces overexpression of growth factors in human keratinocytes
64. Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals
65. Activation of MAPKs in human bronchial epithelial cells exposed to metals
66. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc
67. Arsenite blocks growth factor induced activation of the MAP kinase cascade, upstream of Ras and downstream of Grb2-Sos
68. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling
69. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes
70. Wild-type and Ras-transformed fibroblasts display differential mitogenic responses to transient sodium arsenite exposure
71. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway
72. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding
73. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
74. fra-1: a serum-inducible, cellular immediate-early gene that encodes a fos-related antigen
75. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities
76. Characterization of junD: a new member of the jun proto-oncogene family
77. Transcriptional activation of c-jun during the G0/G1 transition in mouse fibroblasts
78. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage
79. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1
80. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun
81. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells
82. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation
83. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells
84. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells
85. Progressive elevation of AP-1 activity during preneoplastic-to neoplastic progression as modeled in mouse JB6 cell variants
86. c-fos induction by heat, arsenite, and cadmium is mediated by a heat shock element in its promoter
87. Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases
88. Inhibition of arsenite-induced apoptosis and AP-1 activity by epigallocatechin-3-gallate and theaflavins
89. Protein kinase C. Seeing two domains
90. Activation of PKC is required for arsenite-induced signal transduction
91. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
92. Function and activation of NF-kappa B in the immune system
93. The NF-kappa B and I kappa B proteins: new discoveries and insights
94. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity
95. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling
96. The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival
97. Regulation of NF-kappa B activation by MAP kinase cascades
98. Clinically relevant findings
99. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response
100. NF-kappa B: ten years after
101. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B
102. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro
103. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases
104. Roles of nuclear factor kappaB in neuronal survival and plasticity
105. Activation of transcription factor NFκB and p38 mitogen-activated protein kinase is mediated by distinct and separate stress effector pathways
106. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells
107. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase
108. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways
109. Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IkappaB phosphorylation and NF-kappaB activation
110. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study
111. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines
112. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappaB activation
113. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress
114. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis
115. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
116. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice
117. Induction of p53 protein expression by sodium arsenite
118. 3 induces apoptosis of the human B lymphoma cell line MBC-1
119. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts
120. Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts
121. Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts
122. Enhanced phosphorylation of p53 by ATM in response to DNA damage
123. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
124. The role of ATM in DNA damage responses and cancer
125. Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis
126. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice
127. Expression of p53 in arsenic-related and sporadic basal cell carcinoma
128. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan
129. Infrequent p53 mutations in arsenic-related skin lesions
130. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis
131. Sodium arsenite-induced chromosomal aberrations in the Xq arm of Chinese hamster cell lines
132. Variation in arsenic-induced sister chromatid exchange in human lymphocytes and lymphoblastoid cell lines
133. Molecular aspects of arsenic stress
134. Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: a review
135. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2′-deoxyguanosine in arsenic-related Bowen's disease
136. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite
137. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells
138. Arsenite induces DNA-protein crosslinks and cytokeratin expression in the WRL-68 human hepatic cell line
139. DNA damage in arsenite- and cadmium-treated bovine aortic endothelial cells
140. Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: possible involvement of the ubiquitin system in arsenic carcinogenesis
141. Reactions of arsenic(III) and arsenic(V) species with glutathione
142. Arsenic and antimony: comparative approach on mechanistic toxicology
143. Metal carcinogenesis: mechanistic implications
144. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein
145. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro
146. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
147. Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers
148. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore
149. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
150. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis
151. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)
152. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells
153. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis
154. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
155. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
156. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
157. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
158. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells
159. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro
160. Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals
161. Chronic combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice
162. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
163. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis
164. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia
165. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
166. Arsenic: a new place?
167. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
168. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia
169. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
170. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice
171. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
172. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
173. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro
174. 3)
175. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
176. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
177. The biology of chronic myeloid leukemia
178. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
179. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide
180. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1
181. Antitumor effect of arsenic trioxide on mice experimental liver cancer
182. Arsenic-induced apoptosis in malignant cells in vitro
183. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression
184. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines
185. 3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages
186. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro
187. Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase
188. Induction of mitosis-mediated apoptosis by sodium arsenite in HeLa S3 cells
189. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
190. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
191. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells
192. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
193. Sodium arsenite reduces proliferation of human activated T-cells by inhibition of the secretion of interleukin-2